Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review.

Implementation strategies Injectable contraception Scale-up Scoping review Self-care Subcutaneous depot medroxyprogesterone acetate

Journal

Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575

Informations de publication

Date de publication:
04 07 2023
Historique:
received: 24 08 2022
accepted: 06 03 2023
medline: 6 7 2023
pubmed: 5 7 2023
entrez: 4 7 2023
Statut: epublish

Résumé

Self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) is registered in many countries. It shows great potential for improving contraceptive access, continuation, and autonomy. However, there are challenges in rolling out this new efficacious intervention, and major implementation problems have been encountered during scale-up. To describe the implementation strategies to scale up self-administered DMPA-SC and the barriers, facilitators, and outcomes of these programs. Recent guidelines, including the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews, were used to design and report this review. An article or report was eligible for inclusion if it reported interventions that could scale up self-administered DMPA-SC implementation or its facilitators, barriers, or outcomes. We searched six electronic databases and the grey literature for eligible articles and reports. Two reviewers independently screened the document titles, abstracts, and full texts to identify eligible documents. Data were extracted using structured forms. Using the Effective Practice and Organization of Care (EPOC) taxonomy of health systems framework for thematic analysis, data were presented in a narrative approach. Of the 755 retrieved documents, 34 were included in this review. Most of the documents included were multi-country reports (n = 14), and all documents were published within the last 5 years (2018-2021). This review identified documents that reported interventions in all EPOC domains. The most-reported interventions were: task-sharing amongst health workforce cadres, engaged leadership, encouraging policies, training and education, DMPA-SC demand generation, integration into existing programs, improved funding mechanisms, collaboration with development partners, and supply chain strengthening. The main barriers were suboptimal funding, inadequate human resources, and poor logistics supply of DMPA-SC. There was minimal evidence of scale-up outcomes. This scoping review reported a wide range of interventions employed by countries and programs to scale up DMPA-SC self-administration but minimal evidence of the scale-up outcomes. Evidence from this review can help design better programs that improves access to quality family planning services to achieve the Sustainable Development Goals (SDG) targets 3.7. However, efforts should focus on rigorous implementation research that assess scaled up self-administered DMPA-SC interventions and report their outcomes. The protocol for this review was registered in the protocols.io repository ( https://www.protocols.io/view/a-protocol-for-a-scoping-review-of-implementation-x54v9yemmg3e/v1 ).

Sections du résumé

BACKGROUND
Self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) is registered in many countries. It shows great potential for improving contraceptive access, continuation, and autonomy. However, there are challenges in rolling out this new efficacious intervention, and major implementation problems have been encountered during scale-up.
OBJECTIVE
To describe the implementation strategies to scale up self-administered DMPA-SC and the barriers, facilitators, and outcomes of these programs.
METHOD
Recent guidelines, including the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews, were used to design and report this review. An article or report was eligible for inclusion if it reported interventions that could scale up self-administered DMPA-SC implementation or its facilitators, barriers, or outcomes. We searched six electronic databases and the grey literature for eligible articles and reports. Two reviewers independently screened the document titles, abstracts, and full texts to identify eligible documents. Data were extracted using structured forms. Using the Effective Practice and Organization of Care (EPOC) taxonomy of health systems framework for thematic analysis, data were presented in a narrative approach.
RESULTS
Of the 755 retrieved documents, 34 were included in this review. Most of the documents included were multi-country reports (n = 14), and all documents were published within the last 5 years (2018-2021). This review identified documents that reported interventions in all EPOC domains. The most-reported interventions were: task-sharing amongst health workforce cadres, engaged leadership, encouraging policies, training and education, DMPA-SC demand generation, integration into existing programs, improved funding mechanisms, collaboration with development partners, and supply chain strengthening. The main barriers were suboptimal funding, inadequate human resources, and poor logistics supply of DMPA-SC. There was minimal evidence of scale-up outcomes.
CONCLUSION
This scoping review reported a wide range of interventions employed by countries and programs to scale up DMPA-SC self-administration but minimal evidence of the scale-up outcomes. Evidence from this review can help design better programs that improves access to quality family planning services to achieve the Sustainable Development Goals (SDG) targets 3.7. However, efforts should focus on rigorous implementation research that assess scaled up self-administered DMPA-SC interventions and report their outcomes.
REGISTRATION
The protocol for this review was registered in the protocols.io repository ( https://www.protocols.io/view/a-protocol-for-a-scoping-review-of-implementation-x54v9yemmg3e/v1 ).

Identifiants

pubmed: 37403147
doi: 10.1186/s13643-023-02216-2
pii: 10.1186/s13643-023-02216-2
pmc: PMC10318699
doi:

Substances chimiques

Contraceptive Agents, Female 0
Medroxyprogesterone Acetate C2QI4IOI2G

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023. World Health Organization.

Références

JMIR Ment Health. 2018 Jun 26;5(2):e48
pubmed: 29945858
Health Res Policy Syst. 2021 Apr 21;19(Suppl 1):62
pubmed: 33882966
JBI Evid Implement. 2021 Mar;19(1):3-10
pubmed: 33570328
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
J Community Psychol. 2020 Apr;48(3):904-920
pubmed: 31944324
Contraception. 2018 Nov;98(5):449-453
pubmed: 30031000
Stud Fam Plann. 2011 Jun;42(2):67-82
pubmed: 21834409
Implement Sci. 2015 Jun 11;10:88
pubmed: 26062907
Syst Rev. 2021 Jan 26;10(1):39
pubmed: 33499930
Glob Health Sci Pract. 2020 Mar 31;8(1):114-124
pubmed: 32033980
Front Reprod Health. 2021 Aug 04;3:684081
pubmed: 36304027
BMC Womens Health. 2021 Oct 9;21(1):359
pubmed: 34627229
Contraception. 2018 Nov;98(5):411-417
pubmed: 30120925
Contraception. 2018 Nov;98(5):375-378
pubmed: 30145126
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Health Policy Plan. 2020 Mar 1;35(2):219-234
pubmed: 31722382
Contraception. 2017 Mar;95(3):306-311
pubmed: 27789309
Implement Sci. 2021 Jun 12;16(1):62
pubmed: 34118955
Lancet Glob Health. 2018 May;6(5):e568-e578
pubmed: 29526707
BMJ Glob Health. 2019 Apr 02;4(2):e001350
pubmed: 31179026
Implement Sci. 2018 Jul 30;13(1):103
pubmed: 30060744
Health Policy Plan. 2021 Jun 25;36(6):848-860
pubmed: 34009259
Contraception. 2018 Nov;98(5):405-410
pubmed: 29706227
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Reprod Health. 2021 Jan 23;18(1):22
pubmed: 33485339
Contraception. 2020 Dec;102(6):392-395
pubmed: 32931811
Cochrane Database Syst Rev. 2020 Nov 5;11:CD013779
pubmed: 33150970
Reprod Health. 2020 Aug 3;17(1):117
pubmed: 32746860
Open Access J Contracept. 2021 Dec 02;12:187-199
pubmed: 34880691
Contraception. 2017 Sep;96(3):203-210
pubmed: 28673645

Auteurs

Adeniyi Kolade Aderoba (AK)

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. adeniyi.aderoba@gmail.com.
Centre for Population Health and Interdisciplinary Research, Box 603, HealthMATE 360, Ondo Town, Ondo State, 350001, Nigeria. adeniyi.aderoba@gmail.com.

Petrus Schoken Steyn (PS)

UNDP/UNFPA, UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization Headquarters, Geneva, Switzerland.

James Njogu Kiarie (JN)

UNDP/UNFPA, UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization Headquarters, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH